panitumumab
amgen,takeda
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'improve ']
improve phase-ii in ras/braf wt crc 8 cycle folfiri/pani -&gt; break until progression -&gt; folfiri/pani vs continuous folfiri/pani
similar treatment exposure, dcr 94% vs 90%,
pfs 20.2 vs 13.2 left-sided, but 7.9 vs 10 re-sided interesting for left sided crc --&gt; phase-3? 
Physician-scientist, focussed on translational research in hepatobiliary cancer and precision medicine